Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 4, 2007, Pages 333-341

  Fukasawa, T ^a   Suzuki, A ^a   Otani, K ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Benzodiazepine; Cytocrome P450; Pharmacogenetics; Pharmacokinetics; Polymorphism

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BROTIZOLAM; CARBAMAZEPINE; CLOBAZAM; CYTOCHROME P450; CYTOCHROME P450 3A5; CYTOCHROME P450C19; DIAZEPAM; ETIZOLAM; FLUNITRAZEPAM; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; MIDAZOLAM; NORCLOBAZAM; QUAZEPAM; TRIAZOLAM; UNCLASSIFIED DRUG;

ATAXIA; CONFUSION; DROWSINESS; DRUG ABSORPTION; DRUG EFFECT; DRUG METABOLISM; ENZYME DEFICIENCY; ENZYME METABOLISM; GENETIC POLYMORPHISM; HUMAN; IMPAIRED JUDGEMENT; MENTAL DISEASE; PANIC; PHOBIA; REVIEW; SINGLE DRUG DOSE; VERTIGO;

ARYL HYDROCARBON HYDROXYLASES; BENZODIAZEPINES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 34447301028     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00829.x     Document Type: Review

References (68)

1. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210 258.
2. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487 491.
3. Kashuba D, Bertino JS (2001) Mechanisms of drug interactions. In : Piscitelli J, Rodvold K, Masur H, eds. Drug interaction in infectious disease. Totowa : Humana Press, 13 38.
4. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal of Biological Chemistry, 269, 15419 15422.
5. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology, 46, 594 598.
6. Goldstein JA, de Morais SM (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4, 285 299.
7. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 7, 59 64.
8. de Morais SM, Goldstein JA, Xie HG et al. (1995) Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clinical Pharmacology and Therapeutics, 58, 404 411.
9. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics, 10, 373 388.
10. Paine MF, Khalighi M, Fisher JM et al. (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Journal of Pharmacology and Experimental Therapeutics, 283, 1552 1562.
11. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414 423.
12. Eiselt R, Domanski TL, Zibat A et al. (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, 11, 447 458.
13. Lamba JK, Lin YS, Thummel K et al. (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics, 12, 121 132.
14. Kuehl P, Zhang J, Lin Y et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics, 27, 383 391.
15. Schuetz EG, Schuetz JD, Grogan WM et al. (1992) Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Archives of Biochemistry and Biophysics, 294, 206 214.
16. Lin YS, Dowling AL, Quigley SD et al. (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular Pharmacology, 62, 162 172.
17. Aoyama T, Yamano S, Waxman DJ et al. (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. Journal of Biological Chemistry, 264, 10388 10395.
18. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Advanced Drug Delivery Reviews, 54, 1271 1294.
19. Hustert E, Haberl M, Burk O et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics, 11, 773 779.
20. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, Azuma J (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics, 12, 331 334.
21. Shih PS, Huang JD (2002) Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metabolism and Disposition, 30, 1491 1496.
22. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics, 5, 243 272.
23. Hirota N, Ito K, Iwatsubo T et al. (2001) In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharmaceutics and Drug Disposition, 22, 53 71.
24. Park JY, Kim KA, Park PW et al. (2006) Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clinical Pharmacology and Therapeutics, 79, 590 599.
25. Williams JA, Ring BJ, Cantrell VE et al. (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metabolism and Disposition, 30, 883 891.
26. Senda C, Kishimoto W, Sakai K, Nagakura A, Igarashi T (1997) Identification of human cytochrome P450 isoforms involved in the metabolism of brotizolam. Xenobiotica, 27, 913 922.
27. Tokairin T, Fukasawa T, Yasui-Furukori N et al. (2005) Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. British Journal of Clinical Pharmacology, 60, 172 175.
28. Ujiie Y, Fukasawa T, Yasui-Furukori N, Suzuki A, Tateishi T, Otani K (2006) Rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam. Therapeutic Drug Monitoring, 28, 299 302.
29. Contin M, Riva R, Albani F, Baruzzi AA (1999) Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Therapeutic Drug Monitoring, 21, 604 608.
30. Giraud C, Tran A, Rey E, Vincent J, Tréluyer JM, Pons G (2004) In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metabolism and Disposition, 32, 1279 1286.
31. Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T (2004) A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain and Development, 26, 530 534.
32. Parmeggiani A, Posar A, Sangiorgi S, Giovanardi-Rossi P (2004) Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19. Brain and Development, 26, 63 66.
33. Andersson T, Miners JO, Veronese ME, Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology, 38, 131 137.
34. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clinical Pharmacology and Therapeutics, 45, 348 355.
35. Jung F, Richardson TH, Raucy JL, Johnson EF (1997) Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. Drug Metabolism and Disposition, 25, 133 139.
36. Qin XP, Xie HG, Wang W et al. (1999) Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clinical Pharmacology and Therapeutics, 66, 642 646.
37. Araki K, Yasui-Furukori N, Fukasawa T et al. (2004) Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. European Journal of Clinical Pharmacology, 60, 427 430.
38. Fukasawa T, Yasui-Furukori N, Suzuki A, Inoue Y, Tateishi T, Otani K (2005) Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. European Journal of Clinical Pharmacology, 61, 791 795.
39. Kondo S, Fukasawa T, Yasui-Furukori N et al. (2005) Induction of the metabolism of etizolam by carbamazepine in humans. European Journal of Clinical Pharmacology, 61, 185 188.
40. Coller JK, Somogyi AA, Bochner F (1999) Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica, 29, 973 986.
41. Gafni I, Busto UE, Tyndale RF, Kaplan HL, Sellers EM (2003) The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. Journal of Clinical Psychopharmacology, 23, 169 175.
42. Kilicarslan T, Haining RL, Rettie AE, Busto U, Tyndale RF, Sellers EM (2001) Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. Drug Metabolism and Disposition 29, 460 465.
43. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E (1994) Midazolam is metabolized by at least three different cytochrome P450 enzymes. British Journal of Anaesthesia, 73, 658 661.
44. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clinical Pharmacology and Therapeutics, 75, 529 538.
45. Yu KS, Cho JY, Jang IJ et al. (2004) Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clinical Pharmacology and Therapeutics, 76, 104 112.
46. Fujisaki H, Hirotsu K, Ogawa T, Mizuta H, Arima N (2001) Metabolism of quazepam and its metabolites in humans: identification of metabolic enzymes and evaluation of drug interaction in vitro. Xenobiotic Metabolism and Disposition, 16, 558 568 (in Japanese).
47. Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Tateishi T, Otani K (2004) Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity. Therapeutic Drug Monitoring, 26, 529 533.
48. Kato K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Kanno M, Otani K (2003) Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug. Therapeutic Drug Monitoring, 25, 473 477.
49. Kawaguchi A, Ohmori M, Tsuruoka S et al. (2004) Drug interaction between St John's Wort and quazepam. British Journal of Clinical Pharmacology, 58, 403 410.
50. Miura M, Ohkubo T (2004) In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica, 34, 1001 1011.
51. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89 96.
52. Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics, 56, 601 607.
53. Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ. (1997) Triazolam is ineffective in patients taking rifampin. Clinical Pharmacology and Therapeutics, 61, 8 14.
54. Bun H, Coassolo P, Gouezo F, Serradimigni A, Cano JP (1986) Time-dependence of clobazam and N-demethylclobazam kinetics in healthy volunteers. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 24, 287 293.
55. Shorvon SD (1995) Benzodiazepines: clobazam. In : Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. New York : Raven Press, 763 777.
56. Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M (1996) Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia, 37, 728 735.
57. Ghoneim MM, Korttila K, Chiang CK, Jacobs L, Schoenwald RD, Mewaldt SP, Kayaba KO (1981) Diazepam effects and kinetics in Caucasians and Orientals. Clinical Pharmacology and Therapeutics, 29, 749 756.
58. Casacchia M, Bolino F, Ecari U (1990) Etizolam in the treatment of generalized anxiety disorder: a double-blind study versus placebo. Current Medical Research and Opinion, 12, 215 223.
59. Savoldi F, Somenzini G, Ecari U (1990) Etizolam vs. placebo in the treatment of panic disorder with agoraphobia: a double-blind study. Current Medical Research and Opinion, 12, 185 190.
60. Mitsubishi Pharma (2003) Unpublished data in package insert.
61. Scharf MB, Bixler EO, Kales A, Soldatos CR (1979) Long-term sleep laboratory evaluation of flunitrazepam. Pharmacology, 19, 173 181.
62. Cano JP, Sumirtapura YC (1981) Comparative pharmacokinetics of diazepam and flunitrazepam. Annales de l'anesthésiologie française, 22, 175 179 (in French).
63. Ankier SI, Goa KL (1988) Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs, 35, 42 62.
64. Zampaglione N, Hilbert JM, Ning J, Chung M, Gural R, Symchowicz S (1985) Disposition and metabolic fate of 14C-quazepam in man. Drug Metabolism and Disposition, 13, 25 29.
65. Sieghart W (1983) Several new benzodiazepines selectively interact with a benzodiazepine receptor subtype. Neuroscience Letters, 38, 73 78.
66. Hilbert JM, Iorio L, Moritzen V, Barnett A, Symchowicz S, Zampaglione N (1986) Relationships of brain and plasma levels of quazepam, flurazepam, and their metabolites with pharmacological activity in mice. Life Sciences, 39, 161 168.
67. Greenblatt DJ, Wright CE (1993) Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clinical Pharmacokinetics, 24, 453 471.
68. Greenblatt DJ, Harmatz JS, Shader RI (1993) Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder. Archives of General Psychiatry, 50, 715 722.